Lasofoxifene/Abemaciclib Combination Aims to Fill Need in ESR1-Mutant, ER+/HER2- Breast Cancer

Finding effective treatments beyond the first line for patients with locally advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation remains a challenge following development of resistance to agents.

Related Keywords

Minnesota ,United States ,Canada ,Texas ,Houston ,Israel ,Japan ,Mayo Clinic In Rochester ,American ,Ciara Osullivan ,Dsenthil Damodaran ,Eli Lilly ,American Society Of Clinical Oncology Annual Meeting ,Duke Health ,University Of Texas Md Anderson Cancer Center ,Ciarao Sullivan ,Mayo Clinic ,Cancer Center ,Clinical Oncology Annual Meeting ,New Way ,Cancer Treat ,News ,